Biopharma & Life Sciences
Keros Therapeutics Executive Compensation (FY25)
KROS · Executive and director compensation, fiscal 2025 only
Data as of September 7, 2026Latest filing (8-K): June 3, 2026
99 figures on this page: 96 cited to the filing that reported them, 3 calculated from figures it prints. See the citations
Jasbir Seehra was paid $2,540,204 in total compensation as President and Chief Executive Officer for fiscal 2025, and the compensation disclosed runs fiscal 2025 only. Meanwhile, for fiscal 2025, the company reported 4 named executive officers. Separately, shareholders recorded 93.6% support for the say-on-pay proposal at the meeting held June 3, 2026 for fiscal 2025. The disclosed peer group includes Akero Therapeutics, Inc., Arcturus Therapeutics Holdings Inc., Celldex Therapeutics, Inc., Crinetics Pharmaceuticals, Inc. and Disc Medicine, Inc., among others.
This company is not required to report a chief executive pay ratio.
Frequently asked questions
Answers drawn from the data on this page.
Who is Keros Therapeutics' chief executive and what were they paid?
Jasbir Seehra was paid $2,540,204 in total compensation as President and Chief Executive Officer for fiscal 2025.
What was Keros Therapeutics' say-on-pay result?
Shareholders recorded 93.6% support for the say-on-pay proposal at the meeting held June 3, 2026 for fiscal 2025.
Which companies are in Keros Therapeutics' peer group?
The disclosed peer group includes Akero Therapeutics, Inc., Arcturus Therapeutics Holdings Inc., Celldex Therapeutics, Inc., Crinetics Pharmaceuticals, Inc. and Disc Medicine, Inc., among others.
Executive compensation
Every element reported for each named executive officer, by fiscal year.
Fiscal 2025
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Jasbir Seehra President and Chief Executive Officer | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
Christopher Rovaldi Former President and Chief Operating Officer Departed during or after this year | ◇ | — | ◇ | — | — | — | ◇ | ◇ |
Keith Regnante Chief Financial Officer | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
Esther Cho Chief Legal Officer and Secretary | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.
Equity awards granted
Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
| Officer | Award | Grant date | Threshold units | Target units | Units granted | Maximum units | Exercise price | Grant date fair value |
|---|---|---|---|---|---|---|---|---|
| Christopher Rovaldi | OTHER | — | — | — | — | — | — | ◇ |
| Esther Cho | OTHER | — | — | — | — | — | — | ◇ |
| Jasbir Seehra | OTHER | — | — | — | — | — | — | ◇ |
| Keith Regnante | OTHER | — | — | — | — | — | — | ◇ |
Fiscal 2023, 2024 are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.
Outstanding awards
Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
| Officer | Award | Unvested units | Market value of unvested units | Exercise price | Expires |
|---|---|---|---|---|---|
| Keith Regnante | Option | ◇ | — | ◇ | 2/12/2034 |
| Option | ◇ | — | ◇ | 2/15/2033 | |
| Option | ◇ | — | ◇ | 1/20/2032 | |
| RSU | ◇ | ◇ | — | — | |
| Jasbir Seehra | Option | ◇ | — | ◇ | 2/15/2033 |
| Option | ◇ | — | ◇ | 2/12/2034 | |
| Option | ◇ | — | ◇ | 1/20/2032 | |
| RSU | ◇ | ◇ | — | — | |
| PSU | ◇ | ◇ | — | — | |
| Esther Cho | RSU | ◇ | ◇ | — | — |
| Option | ◇ | — | ◇ | 2/12/2034 | |
| Option | ◇ | — | ◇ | 2/15/2033 | |
| Option | ◇ | — | ◇ | 1/20/2032 |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director compensation
What each non-employee director was paid.
Fiscal 2025
| Director | Fees earned in cash | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|
Mary Ann Gray | ◇ | ◇ | ◇ | — | — | — | ◇ |
Nima Farzan | ◇ | ◇ | ◇ | — | — | — | ◇ |
Julius Knowles | ◇ | ◇ | ◇ | — | — | — | ◇ |
Alpna Seth | ◇ | ◇ | ◇ | — | — | — | ◇ |
Carl L. Gordon | ◇ | ◇ | ◇ | — | — | — | ◇ |
Tomer Kariv | ◇ | ◇ | ◇ | — | — | — | ◇ |
Ran Nussbaum | ◇ | ◇ | ◇ | — | — | — | ◇ |
Charles Newton, Jasbir Seehra and Jean-Jacques Bienaim served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director fee schedule
The standing retainers and premiums the board pays, as published.
| Board cash retainer | ◇ |
| Board equity retainer | ◇ |
| Total board retainer | ◇ |
| Lead independent director premium | ◇ |
| Audit committee chair | ◇ |
| Audit committee member | ◇ |
| Compensation committee chair | ◇ |
| Compensation committee member | ◇ |
| Nominating and governance chair | ◇ |
| Nominating and governance member | ◇ |
Disclosed peer group
The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
- Akero Therapeutics, Inc. AKRO
- Arcturus Therapeutics Holdings Inc. ARCT
- Celldex Therapeutics, Inc. CLDX
- Crinetics Pharmaceuticals, Inc. CRNX
- Disc Medicine, Inc. IRON
- Geron Corporation GERN
- IDEAYA Biosciences, Inc. IDYA
- Iovance Biotherapeutics, Inc. IOVA
- KalVista Pharmaceuticals, Inc. KALV
- Kura Oncology, Inc. KURA
- Longboard Pharmaceuticals, Inc. LBPH
- Pliant Therapeutics, Inc. PLRX
- Protagonist Therapeutics, Inc. PTGX
- Relay Therapeutics, Inc. RLAY
- Replimune Group, Inc. REPL
- Rocket Pharmaceuticals, Inc. RCKT
- Scholar Rock Holding Corporation SRRK
- SpringWorks Therapeutics, Inc. SWTX
- Syndax Pharmaceuticals Inc. SNDX
Say-on-pay history
Shareholder support for the compensation program, by year.
| Year | Meeting | Support | Votes for | Votes against | Abstentions |
|---|---|---|---|---|---|
| 2025 | June 3, 2026 | = | ◇ | ◇ | ◇ |
| 2024 | June 4, 2025 | = | ◇ | ◇ | ◇ |
| 2023 | May 30, 2024 | = | ◇ | ◇ | ◇ |
What this page does not include
Everything above is a fact Keros Therapeutics disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Keros Therapeutics sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $1,200Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion IntelligenceAdviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Enquire about accessMultiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion IntelligenceCitations
Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
99 figures on this page: 96 cited to the filing that reported them, 3 calculated from figures it prints.
96 cited to the filing
3 calculated from the filing
Documents cited
- 0001664710-26-000034
- 0001104659-26-046791EXECUTIVE COMPENSATION · NON-EMPLOYEE DIRECTOR COMPENSATION · Non-Employee Director Compensation Policy · Outstanding Equity Awards as of December 31, 2025 · and 1 more section
- 0001664710-25-000057
- 0001664710-24-000045
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Keros Therapeutics executive compensation, FY2025.” https://intel.velarion.ai/comp/KROS (accessed 2026).
Short form: data: Velarion
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Keros Therapeutics and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Biopharma & Life Sciences rankings
Peers Keros Therapeutics discloses
The companies named in KROS's own disclosed peer group.
Terms on this page
Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
author = {{Velarion Company Intelligence}},
title = {Velarion database: executive and board compensation data},
year = {2026},
version = {2026Q3},
doi = {10.5281/zenodo.22283854},
publisher = {Zenodo},
url = {https://doi.org/10.5281/zenodo.22283854}
}